logo-loader

RedHill Biopharma COVID-19 treatment candidate better than Gilead’s remdesivir in lab test

Published: 10:37 08 Sep 2020 EDT

RedHill Biopharma - RedHill Biopharma COVID-19 treatment candidate better than Gilead’s remdesivir in lab test

RedHill Biopharma (NASDAQ:RDHL) announced its COVID-19 treatment candidate showed promising results in laboratory test.

Opaganib demonstrated "potent inhibition" of SARS-CoV-2, the virus that causes COVID-19, in an in vitro model of human lung bronchial tissue.

READ: Anger as US snaps up supplies of Gilead coronavirus treatment Remdesivir

It also compared favourably with remdesivir, the treatment developed by Gilead Sciences, Inc. (NASDAQ:GILD) and used in the US.

The candidate is under evaluation in global Phase 2/3 and US Phase 2 studies on humans for the treatment of severe COVID-19 pneumonia.

“We are accelerating progress toward our goal of generating a robust data package to potentially support emergency use authorisations for COVID-19,” said Mark L. Levitt, medical director at RedHill.

Shares advanced 10% to US$8.16 on Tuesday.

RedHill Biopharma shows strong inhibition by opaganib of the coronavirus...

RedHill Biopharma (NASDAQ:RDHL) Ltd (NASDAQ:RDHL) chief business officer Guy Goldberg caught up with Proactive New York to speak on results of its new preclinical study, which he says demonstrated strong inhibition by its investigational oral pill opaganib of the coronavirus Delta variant...

on 27/8/21